Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases

BACKGROUND: HER2-low breast cancers (BC) show a good response to novel anti-HER2 antibody-drug conjugates (ADCs) in advanced setting. Nevertheless, little is known about the response, category change, and prognosis of HER2-low BC receiving neoadjuvant treatment (NAT). METHODS: Consecutive invasive B...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Siji, Lu, Yujie, Fei, Xiaochun, Shen, Kunwei, Chen, Xiaosong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575949/
https://www.ncbi.nlm.nih.gov/pubmed/37604930
http://dx.doi.org/10.1038/s41416-023-02403-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575949/
https://www.ncbi.nlm.nih.gov/pubmed/37604930
http://dx.doi.org/10.1038/s41416-023-02403-x

Ejemplares similares